Canaccord analyst Whitney Ijem lowered the firm’s price target on Passage Bio (PASG) to $23 from $67 and keeps a Buy rating on the shares. The firm updated it model following the most recent update for its lead program FTD-GRN and FTD-C9orf72. The The company has responded appropriately with protocol amendments and, importantly, continued to enroll and dose patients across two cohorts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG:
- Passage Bio Reports 2025 Results, Advances FTD Program
- Passage Bio reports Q4 EPS ($4.09), consensus ($2.80)
- Passage Bio sees cash runway through 1Q27
- Passage Bio: Market Overreaction to AAV Oncogenesis Risk Creates Compelling Buy Opportunity Ahead of 2026 PBFT02 Catalysts
- Passage Bio Highlights PBFT02 Progress and Extended Cash Runway